Goetz Matthew P, Callstrom Matthew R, Charboneau J William, Farrell Michael A, Maus Timothy P, Welch Timothy J, Wong Gilbert Y, Sloan Jeff A, Novotny Paul J, Petersen Ivy A, Beres Robert A, Regge Daniele, Capanna Rodolfo, Saker Mark B, Grönemeyer Dietrich H W, Gevargez Athour, Ahrar Kamran, Choti Michael A, de Baere Thierry J, Rubin Joseph
Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
J Clin Oncol. 2004 Jan 15;22(2):300-6. doi: 10.1200/JCO.2004.03.097.
Few options are available for pain relief in patients with bone metastases who fail standard treatments. We sought to determine the benefit of radiofrequency ablation (RFA) in providing pain relief for patients with refractory pain secondary to metastases involving bone.
Thirty-one US and 12 European patients with painful osteolytic metastases involving bone were treated with image-guided RFA using a multitip needle. Treated patients had > or = 4/10 pain and had either failed or were poor candidates for standard treatments such as radiation or opioid analgesics. Using the Brief Pain Inventory-Short Form, worst pain intensity was the primary end point, with a 2-unit drop considered clinically significant.
Forty-three patients were treated (median follow-up, 16 weeks). Before RFA, the mean score for worst pain was 7.9 (range, 4/10 to 10/10). Four, 12, and 24 weeks following treatment, worst pain decreased to 4.5 (P <.0001), 3.0 (P <.0001), and 1.4 (P =.0005), respectively. Ninety-five percent (41 of 43 patients) experienced a decrease in pain that was considered clinically significant. Opioid usage significantly decreased at weeks 8 and 12. Adverse events were seen in 3 patients and included (1) a second-degree skin burn at the grounding pad site, (2) transient bowel and bladder incontinence following treatment of a metastasis involving the sacrum, and (3) a fracture of the acetabulum following RFA of an acetabular lesion.
RFA of painful osteolytic metastases provides significant pain relief for cancer patients who have failed standard treatments.
对于标准治疗无效的骨转移患者,缓解疼痛的选择有限。我们试图确定射频消融(RFA)为继发于骨转移的难治性疼痛患者缓解疼痛的益处。
31名美国患者和12名欧洲患者因溶骨性骨转移疼痛接受了使用多尖针的影像引导下RFA治疗。接受治疗的患者疼痛程度≥4/10,且对放疗或阿片类镇痛药等标准治疗无效或不适合。使用简明疼痛问卷简表,最严重疼痛强度是主要终点,下降2个单位被认为具有临床意义。
43名患者接受了治疗(中位随访时间为16周)。RFA治疗前,最严重疼痛的平均评分为7.9(范围为4/10至10/10)。治疗后4周、12周和24周,最严重疼痛分别降至4.5(P<.0001)、3.0(P<.0001)和1.4(P =.0005)。95%(43名患者中的41名)经历了被认为具有临床意义的疼痛减轻。阿片类药物的使用在第8周和第12周显著减少。3名患者出现了不良事件,包括(1)接地垫部位二度皮肤烧伤,(2)骶骨转移瘤治疗后短暂的肠道和膀胱失禁,以及(3)髋臼病变RFA后髋臼骨折。
对于标准治疗无效的癌症患者,溶骨性骨转移疼痛的RFA可显著缓解疼痛。